$ProShares Ultra纳斯达克生物科 (BIB.US)$was climbing 1.5%. $SciSparc (SPRC.US)$rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing. $Glaukos (GKOS.US)$gained 6% after We...
Glaukos股票讨论区
$Arcutis Biotherapeutics (ARQT.US)$ : 已批准 12/15
• ZORYVE®(罗氟拉麦乐泡沫0.3%)
⇒ 局部泡沫
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ 脂溢性皮炎
$默沙东 (MRK.US)$ : 2021年12月15日获得批准
• KEYTRUDA(帕博替尼马布)+ Padcev(恩福利单抗-伊贝法金)
⇒ 静脉注射
⇒ PDUFA:05/09/24
⇒ sBLA
⇒ 膀胱上皮癌
$Glaukos (GKOS.US)$ : 通过 12/14
• iDose® TR(咪芬洛酮)
⇒ 眼房角内植入物
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ 青光眼
$默沙东 (MRK.US)$ : 已批准 ...
加入我们以互相连接和分享,并快速获取信息!
$CRISPR Therapeutics (CRSP.US)$ $福泰制药 (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $安进 (AMGN.US)$ $默沙东 (MRK.US)$
我在这里看到了一些不错的上行图表
想法?
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after We...
• $Canoo (GOEV.US)$ +71.3%(从沃尔玛获得购买订单,订购4500辆Canoo电动交付车辆)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1%(在干眼病室交叉临床试验中达到主要终点)
• $西港燃料 (WPRT.US)$ +10.9%(获得3800万项目奖励)
• $Greenwich LifeSciences (GLSI.US)$ +5.9%(FDA已经移除了临床暂停,允许Flamingo-01第三期临床试验继续进行...
暂无评论